Latest news with #Xgeva
Yahoo
29-05-2025
- Business
- Yahoo
Denosumab Market Report 2025-2029 & 2034: Strategic Collaborations and Digital Health Pave the Way for Innovations, First-Line Treatment Boyoubei Gains Traction
Explore the booming denosumab market, projected to reach $5.59 billion by 2029 with a CAGR of 10.9%. Key growth drivers include osteoporosis prevalence, innovative treatments, and strategic partnerships. Major players like Amgen and Boan Biotech are at the forefront, with North America leading and Asia-Pacific emerging rapidly. Denosumab Market Dublin, May 29, 2025 (GLOBE NEWSWIRE) -- The "Denosumab Market Report 2025" has been added to offering. The denosumab market has experienced robust growth, increasing from $3.27 billion in 2024 to an expected $3.7 billion in 2025, registering a CAGR of 13.1%. This growth has been supported by clinical trials, research advancements, FDA approvals, an increased focus on bone health, and strategic partnerships. As the demand continues, projections indicate the market will reach $5.59 billion by 2029, with a CAGR of 10.9% for the forecast period. This anticipated growth is linked to a rising incidence of bone metastases and advancements in both cancer therapies and osteoporosis awareness. Recent studies, including one from the National Center for Biotechnology Information, highlight the prevalence of osteoporosis, with figures such as a 12.7% prevalence in women diagnosed by physicians in Canada. These statistics underscore the expanding need for effective treatments like denosumab, which targets bone resorption, thereby aiding in reducing fracture risks. Key market players are enhancing their offerings, as seen with Boan Biotech's November 2022 introduction of Boyoubei, a denosumab biosimilar. Securing approval from China's National Medical Products Administration, this biosimilar stands unique as the first to receive global marketing approval. Strategies include penetration into the U.S. and European markets with hopes to impact osteoporosis treatment guidelines. Strategic collaborations are shaping the market. For instance, in June 2022, Organon entered into a partnership with Henlius to commercialize biosimilar candidates referencing Prolia and Xgeva (Denosumab). This alliance emphasizes Organon's commitment to affordable healthcare, particularly focusing on women's health. Major companies in this market include Johnson & Johnson, F. Hoffmann-La Roche Ltd., Novartis International AG, and Amgen Inc., among others. With North America leading the market in 2024, Asia-Pacific is expected to be the fastest-growing region due to rising healthcare advancements and awareness. The denosumab market includes sales of calcium and vitamin D supplements, with values representing factory-gate sales, encompassing the goods sold by manufacturers to various entities. The market also covers comprehensive reports addressing market size, regional shares, and detailed segments, providing a holistic perspective of industry trends. This market, valued in USD unless specified, includes revenues from direct sales, highlighting its importance across multiple geographies, including Asia-Pacific, Western and Eastern Europe, North America, and beyond. Denosumab, as a monoclonal antibody, plays a critical role in treating bone-related conditions, specifically osteoporosis and bone metastases, revealing its ongoing importance in the healthcare landscape. Key Attributes: Report Attribute Details No. of Pages 200 Forecast Period 2025 - 2029 Estimated Market Value (USD) in 2025 $3.7 Billion Forecasted Market Value (USD) by 2029 $5.59 Billion Compound Annual Growth Rate 10.9% Regions Covered Global Scope: Markets Covered: By Drug Classification:Prolia, Xgeva, Others By Type:60 mg, 120 mg By End-Users:Hospitals, Homecare, Specialty Clinics, Ambulatory Surgical Centers Companies Featured Johnson & Johnson F. Hoffmann-La Roche Ltd. Novartis International AG Sanofi SA GlaxoSmithKline plc Eli Lilly and Company Amgen Inc. Asahi Kasei Corporation Teva Pharmaceutical Industries Ltd. Astellas Pharma Inc. Daiichi Sankyo Company, Limited Mylan N.V. Sandoz International GmbH Daiichi Sankyo Company Limited Aurobindo Pharma Limited Cipla Limited Dr. Reddy's Laboratories Ltd. Hikma Pharmaceuticals PLC Celltrion Inc. Amneal Pharmaceuticals Inc Cadila Healthcare Limited Lupin Limited Biocon Limited Torrent Pharmaceuticals Ltd. Jubilant Life Sciences Limited Ajanta Pharma Limited For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Denosumab Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
Yahoo
29-05-2025
- Business
- Yahoo
Denosumab Market Report 2025-2029 & 2034: Strategic Collaborations and Digital Health Pave the Way for Innovations, First-Line Treatment Boyoubei Gains Traction
Explore the booming denosumab market, projected to reach $5.59 billion by 2029 with a CAGR of 10.9%. Key growth drivers include osteoporosis prevalence, innovative treatments, and strategic partnerships. Major players like Amgen and Boan Biotech are at the forefront, with North America leading and Asia-Pacific emerging rapidly. Denosumab Market Dublin, May 29, 2025 (GLOBE NEWSWIRE) -- The "Denosumab Market Report 2025" has been added to offering. The denosumab market has experienced robust growth, increasing from $3.27 billion in 2024 to an expected $3.7 billion in 2025, registering a CAGR of 13.1%. This growth has been supported by clinical trials, research advancements, FDA approvals, an increased focus on bone health, and strategic partnerships. As the demand continues, projections indicate the market will reach $5.59 billion by 2029, with a CAGR of 10.9% for the forecast period. This anticipated growth is linked to a rising incidence of bone metastases and advancements in both cancer therapies and osteoporosis awareness. Recent studies, including one from the National Center for Biotechnology Information, highlight the prevalence of osteoporosis, with figures such as a 12.7% prevalence in women diagnosed by physicians in Canada. These statistics underscore the expanding need for effective treatments like denosumab, which targets bone resorption, thereby aiding in reducing fracture risks. Key market players are enhancing their offerings, as seen with Boan Biotech's November 2022 introduction of Boyoubei, a denosumab biosimilar. Securing approval from China's National Medical Products Administration, this biosimilar stands unique as the first to receive global marketing approval. Strategies include penetration into the U.S. and European markets with hopes to impact osteoporosis treatment guidelines. Strategic collaborations are shaping the market. For instance, in June 2022, Organon entered into a partnership with Henlius to commercialize biosimilar candidates referencing Prolia and Xgeva (Denosumab). This alliance emphasizes Organon's commitment to affordable healthcare, particularly focusing on women's health. Major companies in this market include Johnson & Johnson, F. Hoffmann-La Roche Ltd., Novartis International AG, and Amgen Inc., among others. With North America leading the market in 2024, Asia-Pacific is expected to be the fastest-growing region due to rising healthcare advancements and awareness. The denosumab market includes sales of calcium and vitamin D supplements, with values representing factory-gate sales, encompassing the goods sold by manufacturers to various entities. The market also covers comprehensive reports addressing market size, regional shares, and detailed segments, providing a holistic perspective of industry trends. This market, valued in USD unless specified, includes revenues from direct sales, highlighting its importance across multiple geographies, including Asia-Pacific, Western and Eastern Europe, North America, and beyond. Denosumab, as a monoclonal antibody, plays a critical role in treating bone-related conditions, specifically osteoporosis and bone metastases, revealing its ongoing importance in the healthcare landscape. Key Attributes: Report Attribute Details No. of Pages 200 Forecast Period 2025 - 2029 Estimated Market Value (USD) in 2025 $3.7 Billion Forecasted Market Value (USD) by 2029 $5.59 Billion Compound Annual Growth Rate 10.9% Regions Covered Global Scope: Markets Covered: By Drug Classification:Prolia, Xgeva, Others By Type:60 mg, 120 mg By End-Users:Hospitals, Homecare, Specialty Clinics, Ambulatory Surgical Centers Companies Featured Johnson & Johnson F. Hoffmann-La Roche Ltd. Novartis International AG Sanofi SA GlaxoSmithKline plc Eli Lilly and Company Amgen Inc. Asahi Kasei Corporation Teva Pharmaceutical Industries Ltd. Astellas Pharma Inc. Daiichi Sankyo Company, Limited Mylan N.V. Sandoz International GmbH Daiichi Sankyo Company Limited Aurobindo Pharma Limited Cipla Limited Dr. Reddy's Laboratories Ltd. Hikma Pharmaceuticals PLC Celltrion Inc. Amneal Pharmaceuticals Inc Cadila Healthcare Limited Lupin Limited Biocon Limited Torrent Pharmaceuticals Ltd. Jubilant Life Sciences Limited Ajanta Pharma Limited For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Denosumab Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
20-05-2025
- Business
- Yahoo
Amgen vs Bristol Myers: Which Biotech Giant Has Better Prospects?
Amgen AMGN and Bristol Myers Squibb BMY are among the largest global biotechnology companies with broad and diverse portfolios. Amgen boasts one of the largest portfolios in the biotech industry with a strong presence in the oncology, cardiovascular disease, inflammation, bone health and rare disease markets. Bristol Myers is focused on discovering, developing and delivering transformational drugs for oncology, hematology, immunology, cardiovascular, neuroscience and other diseases. Both of these biotech giants have established strong footholds in their respective target markets, delivering consistent returns to shareholders. In such a scenario, choosing one stock over another can be challenging. Let us delve into their fundamentals, potential growth prospects, challenges and valuation levels to make a prudent choice. With a vast global footprint, Amgen's diverse portfolio has positioned it well in the evolving biotech industry. Growth products like Prolia, Xgeva, Evenity, Vectibix, Nplate and Kyprolis and Blincyto have performed well on consistent label expansions. Robust growth from these products has stabilized the company's revenue base in the face of declining sales from legacy drugs. However, increased pricing headwinds and competitive pressure are negatively impacting the sales of many products. Sales of best-selling drugs, Prolia and Xgeva, are expected to decline in 2025, mainly from the second half, due to biosimilar competition. Nonetheless, Repatha, a key drug in Amgen's arsenal, is driving the growth trajectory. The approval of Tezspire/tezepelumab to treat severe asthma has also strengthened the company's portfolio. Amgen has promising candidates in its pipeline, which represent significant commercial potential. Amgen plans to conduct a broad phase III program on MariTide across obesity, obesity-related conditions and type-II diabetes. Amgen expects data readouts from the ongoing phase II study in type II diabetes and part II of the ongoing phase II study in obesity in the second half of 2025. Amgen also boasts a strong biosimilars portfolio. Approvals of Wezlana and Pavblu have strengthened this portfolio. With a robust cash balance, Amgen is continually seeking strategic deals to expand its business. The acquisition of Horizon Therapeutics has significantly expanded Amgen's rare disease business by adding several rare disease drugs, including Tepezza, Krystexxa and Uplizna, to its portfolio. BMY's Growth Portfolio, comprising drugs like Reblozyl, Breyanzi, Camzyos and Opdualag, has stabilized its revenue base amid generic competition for its legacy drugs. Thalassemia drug Reblozyl has put up a stellar performance since its approval, with strong growth in the United States and international markets. The drug is expected to contribute significantly in the coming decade. Sales of its oncology drug, Opdualag, have also been robust, fueling the top line. Strong growth in the U.S. market and encouraging uptake in newly launched markets have boosted sales. Strong momentum in Camzyos should further drive growth. Opdivo continues to maintain momentum on consistent label expansions. The FDA approval of Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) injection for subcutaneous use should help extend the impact of its immuno-oncology franchise to patients into the next decade. Other drugs like Zeposia and Krazati should also contribute to top-line growth. The company has made strategic acquisitions to broaden its portfolio and drive top-line growth. The recent FDA approval for xanomeline and trospium chloride (formerly KarXT), an oral medication for the treatment of schizophrenia in adults, was approved under the brand name Cobenfy. The approval of Cobenfy for schizophrenia broadens BMY's portfolio and validates the acquisition of Karuna Therapeutics. While the newer drugs boost sales, generic competition for legacy drugs, which account for the majority of total revenues, is a significant headwind and will affect top-line growth in the near term. Legacy Portfolio revenues declined 20% in the first quarter due to continued generic impact on Revlimid, Pomalyst, Sprycel and Abraxane, as well as the U.S. Medicare Part D redesign effect. Nonetheless, BMY is looking to boost its bottom line through cost-cutting initiatives. While BMY's strategy of acquiring companies with promising drugs and candidates is encouraging, this has resulted in substantial debt to finance these acquisitions. As of March 31, 2025, the company had cash and equivalents of $12.1 billion and a long-term debt of $46.1 billion. The Zacks Consensus Estimate for AMGN's 2025 sales implies a year-over-year increase of 5.31%, and that for earnings per share (EPS) suggests a year-over-year improvement of 4.79%. EPS estimates for 2025 have moved north in the past 60 days. However, the metric for 2026 has moved south during the same time frame. Image Source: Zacks Investment Research The Zacks Consensus Estimate for BMY's 2025 sales implies a year-over-year decrease of 4.10% while that for EPS suggests a year-over-year increase of 499.13%. EPS estimates for 2025 have moved north in the past 60 days, but the same for 2026 has remained unchanged during the said timeframe. Image Source: Zacks Investment Research From a price-performance perspective, AMGN has fetched better returns than BMY so far this year. Shares of AMGN have gained 6.2%, while those of BMY have lost 15.5%. The industry has declined 6.2% in the said period. Image Source: Zacks Investment Research From a valuation standpoint, as the biotech industry has very few players with approved drugs, we use the P/E ratio of the large-cap pharma industry to compare these companies. Going by the same, AMGN is more expensive than BMY. AMGN's shares currently trade at 13X forward earnings, higher than 7.10 for Source: Zacks Investment Research AMGN and BMY's attractive dividend yield is a strong positive for investors. However, BMY's dividend yield of 5.30% is higher than AMGN's 3.49%. Large biotech companies are generally considered safe havens for investors interested in this sector. However, with both AMGN and BMY currently carrying a Zacks Rank #3 (Hold), choosing one stock over the other is a complex task. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. AMGN's strong and diverse portfolio should enable it to maintain growth. Key drugs like Evenity and Repatha, as well as newer drugs like Tavneos and Tezspire, continue to drive growth and offset the revenue decline from oncology biosimilars and legacy drugs like Enbrel. BMY's efforts to revive the top line in the face of generic challenges for key drugs are commendable. However, we believe there is still time before the efforts reap a harvest for the company. The outlook for 2025 indicates challenges as of now. Hence, AMGN is a better pick at present (despite its pricey valuation) as we believe there is room for growth buoyed by solid fundamentals and recent positive estimate revisions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Bristol Myers Squibb Company (BMY) : Free Stock Analysis Report Amgen Inc. (AMGN) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Wales Online
22-04-2025
- Health
- Wales Online
'I thought symptoms were just being a mum so cancer spread for three years'
'I thought symptoms were just being a mum so cancer spread for three years' Doctors told Kate she had sciatica and she wasn't offered an x-ray Kate Crawford initially blamed her tiredness and other minor symptoms on her busy life as a mother of three very young children (Image: Cover Images ) A young mum who was told she was suffering from sciatica by doctors was later diagnosed with stage 4 breast cancer. Kate Crawford initially blamed her tiredness and other minor symptoms on her busy life as a mother of three very young children. By the time she was diagnosed the disease had been silently spreading through her body for two to three years, leaving her no choice but to have radical treatment. 'If the doctor had just done an x-ray, he would've seen I had cancer,' she says. 'One day, I was a 28-year-old mum of babies, and the next, I was being told I might not be here much longer. I didn't know what to look for. I just thought I was tired because I was a new mum. But it wasn't just exhaustion - I was feeling excessively tired all the time, I had constant belly issues, a nagging cough that wouldn't go away, and pain in my bones that never seemed to improve. 'There were changes in my breasts that I didn't recognise as warning signs, bruises that didn't go away, and skin issues that I brushed off. I honestly thought I was just rundown. If I had been more educated in the signs, I might have been able to better advocate for myself. It may be too late for me, but it's not for you. If something doesn't feel right, please don't ignore it.' She immediately started aggressive treatment; harsh chemotherapy, targeted therapies like Herceptin and Perjeta, and a shot of Xgeva to help with bone metastases. Now 41, Kate has had 200 plus treatments including a double mastectomy and spent nearly a third of her life in a relentless battle for survival. Her husband Steve has been constantly at her side along with their children, twins Grace and Lily, now 16, and Stephen, 15. She says Steve is her anchor. At times her treatment has been far from straightforward. She has had allergic reactions, heart failure and even developed early-stage lung disease. Article continues below Kate and her children 'Whenever my heart isn't doing well, I have to stop Herceptin and then the cancer starts growing again,' she explains. 'It's just this really crazy cycle.' Kate has kept fighting, adapting her life around the three week treatment cycle and her changing body. 'A stage 4 diagnosis means treatment for life and side effects for life,' she says. 'When one thing pops up, you just have to deal with it. Take it one step at a time. That time lets me relax and unwind. It reminds me to look for the glimmers.' She concentrates on small joys - from floating in a lake on a calm day, laughing with her kids, or discovering a new jumper that fits just right. 'I just want to keep making memories with my family. That's all I've ever wanted,' she says. She shares her life on TikTok with humour and brutal honesty about the challenges cancer patients face every day. One video shows her trying on swimwear post-mastectomy and struggling to find any that fit just right. 'I've never tried to sugarcoat my life, but people forget the daily struggles,' she says. 'We hide a lot, not for ourselves but to make others feel better.' She warns against toxic positivity. 'It's ok to feel not ok. You don't always have to be the brave, stoic cancer patient,' she says. 'You can be mad, bitter, sad and still be full of love. That is perfectly ok. Kate Crawford 'Getting diagnosed with cancer is like jumping into a big metaphorical lake full of other cancer patients. We're all in there together, but we can't help each other. We carefully tread water, but we get tired. Sometimes we barely hang on. People cheer from the shore. Some get rescued. Others stay. Some never make it out.' Article continues below Kate works as a social media manager and family support specialist at One Day to Remember, a nonprofit close to her heart. 'They provide solace and unforgettable experiences to families affected by cancer. The emotional trauma these families go through is staggering,' she says. 'But One Day to Remember makes sure they get to experience joy - even in the most challenging times.' And despite a terminal diagnosis, Kate is still full of life. Her message is clear: You are never too young to get cancer. And sometimes, what feels like exhaustion or a stubborn cough can be something more serious. 'I didn't know the signs,' she says. 'That's what I want people to take away from this. Know your body. Don't ignore your gut. It might just save your life.'
Korea Herald
04-03-2025
- Business
- Korea Herald
Celltrion secures FDA approval for bone disease biosimilars
Celltrion announced Tuesday that its biosimilars Stoboclo and Osenvelt, referencing bone disease treatments Prolia and Xgeva (denosumab), have received marketing approval from the US Food and Drug Administration. Stoboclo is approved for treating postmenopausal osteoporosis in women, while Osenvelt is indicated for the prevention of skeletal-related complications in cancer patients with bone metastases and for giant cell tumors of bone. Both products have been approved for all indications covered by the original reference drugs in the US. Prolia and Xgeva recorded approximately $6.59 billion combined in global sales in 2023, with the US market alone accounting for two-thirds of that at $4.39 billion. Celltrion plans to launch Stoboclo and Osenvelt in the US market as early as this year, following the completion of a patent settlement agreement with the original drug developer. In November, Celltrion became the first company in Korea to obtain approval for these biosimilars, ahead of competing products. It also secured approval from the European Commission last month, accelerating its efforts to expand sales in major global markets. Celltrion has been making aggressive moves to broaden its treatment portfolio, gaining approval for biosimilars for autoimmune diseases, oncology, ophthalmology and bone disease across key global markets. So far this year, the company has obtained three product approvals in the US and four in Europe, totaling seven across both markets. The company last year already surpassed its goal of establishing an 11-product portfolio in Korea by 2025. It recently met the same goal in Europe. "Our recent approvals in major global markets reaffirm our in-house biosimilar development capabilities," a Celltrion official said. "We will focus on completing the remaining regulatory approvals for our pipeline products while ensuring the rapid market penetration of approved products to drive revenue growth."
